A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

274

Participants

Timeline

Start Date

April 25, 2019

Primary Completion Date

June 29, 2022

Study Completion Date

April 17, 2023

Conditions
Nonradiographic Axial Spondyloarthritis
Interventions
DRUG

Bimekizumab

Subjects will receive bimekizumab at pre-specified time-points.

OTHER

Placebo

Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.

Trial Locations (83)

16635

As0010 50020, Duncansville

21740

As0010 50015, Hagerstown

32174

As0010 50059, Ormond Beach

34239

As0010 50056, Sarasota

63141

As0010 50016, St Louis

75150

As0010 50036, Mesquite

75231

As0010 50057, Dallas

85032

As0010 50052, Phoenix

85210

As0010 50131, Mesa

85351

As0010 50062, Sun City

91786

As0010 50060, Upland

99204

As0010 50061, Spokane

97239-3011

As0010 50055, Portland

38119-5214

As0010 50012, Memphis

Unknown

As0010 40004, Brussels

As0010 40003, Genk

As0010 40001, Ghent

As0010 40002, Merksem

As0010 40006, Plovdiv

As0010 40007, Plovdiv

As0010 40005, Sofia

As0010 40008, Sofia

As0010 20040, Beijing

As0010 20021, Chengdu

As0010 20019, Guangzhou

As0010 20034, Hefei

As0010 20024, Nanjing

As0010 20018, Shanghai

As0010 20020, Shanghai

As0010 20026, Shanghai

As0010 20025, Wenzhou

As0010 40011, Brno

As0010 40009, Pardubice

As0010 40013, Prague

As0010 40014, Prague

As0010 40015, Prague

As0010 40016, Prague

As0010 40010, Uherské Hradiště

As0010 40012, Zlín

As0010 40018, Boulogne-Billancourt

As0010 40022, Limoges

As0010 40025, Berlin

As0010 40029, Hamburg

As0010 40024, Hanover

As0010 40027, Herne

As0010 40078, Leipzig

As0010 40026, Ratingen

As0010 40032, Debrecen

As0010 40031, Szeged

As0010 40033, Székesfehérvár

As0010 40080, Szombathely

As0010 20030, Chūōku

As0010 20039, Iruma-gun

As0010 20036, Kawachi-Nagano

As0010 20045, Kita-gun

As0010 20065, Kitakyushu

As0010 20038, Nankoku-shi

As0010 20037, Osaka

As0010 20084, Saga

As0010 20048, Saitama

As0010 20031, Sapporo

As0010 20035, Tokyo

As0010 40038, Elblag

As0010 40042, Krakow

As0010 40037, Lublin

As0010 40044, Poznan

As0010 40040, Torun

As0010 40041, Warsaw

As0010 40039, Wroclaw

As0010 40043, Wroclaw

As0010 40045, A Coruña

As0010 40046, Córdoba

As0010 40047, Madrid

As0010 40048, Santiago de Compostela

As0010 40049, Seville

As0010 40052, Ankara

As0010 40053, Ankara

As0010 40050, Istanbul

As0010 40051, Izmir

As0010 40057, Edinburgh

As0010 40056, Leeds

As0010 40054, London

As0010 40055, Norwich

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT03928704 - A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis | Biotech Hunter | Biotech Hunter